Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study

Lueftner, Diana; Tesch, Hans; Schmidt, Marcus; Hartkopf, Andreas D.; Streicher, Sarah; Resch, Anna; Genovese, Luca; Rose, Christian; Valenti, Roberta; Harbeck, Nadia

dc.contributor.author	Hartkopf, Andreas
dc.date.accessioned	2021-11-22T09:34:30Z
dc.date.available	2021-11-22T09:34:30Z
dc.date.issued	2021
dc.identifier.issn	1879-0852
dc.identifier.uri	http://hdl.handle.net/10900/120915
dc.language.iso	en	de_DE
dc.publisher	Elsevier Sci Ltd	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/j.ejca.2021.03.045	de_DE
dc.subject.ddc	610	de_DE
dc.title	Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study	de_DE
dc.type	Article	de_DE
utue.quellen.id	20210824232002_01021
utue.publikation.seiten	268-277	de_DE
utue.personen.roh	Lueftner, Diana
utue.personen.roh	Tesch, Hans
utue.personen.roh	Schmidt, Marcus
utue.personen.roh	Hartkopf, Andreas D.
utue.personen.roh	Streicher, Sarah
utue.personen.roh	Resch, Anna
utue.personen.roh	Genovese, Luca
utue.personen.roh	Rose, Christian
utue.personen.roh	Valenti, Roberta
utue.personen.roh	Harbeck, Nadia
dcterms.isPartOf.ZSTitelID	European Journal of Cancer	de_DE
dcterms.isPartOf.ZS-Volume	150	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE